Literature DB >> 844497

On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs.

B H Westerink, B Lejeune, J Korf, H M Van Praag.   

Abstract

3,4-Dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured in the corpus striatum, nucleus accumbens and tuberculum olfactorium of the rat brain, 4 antidepressants, 4 anesthetics, dipropylacetate, ethosuximide and metoclopramide induced a rise of DOPAC and HVA levels in the 3 brain regions. No change was observed after carbamazepine, diazepam or propranolol treatment. Combined treatment with a maximally effective dose of haloperidol and morphine, oxotremorine or probenecid produced an additional rise of DOPAC and HVA levels, while no additional rise was seen with chloral hydrate, chlorimipramine, ether, halothane, metoclopramide or sulpiride. The potency of drugs to increase DA metabolism in corpus striatum relative to mesolimbic structures was estimated. Atypical neuroleptics such as sulpiride could be differentiated in this respect from classical neuroleptics such as chlorpromazine, fluphenazine and thioridazine, by their ability to produce a relatively large increase of metabolite levels in the mesolimbic regions. The heterogeneous group of 14 non-neuroleptics however produced regional changes which were very similar to those of the atypical neuroleptics. DA metabolism in mesolimbic regions, in contrast to striatal tissue, seems to respond more to atypical neuroleptics and non-neuroleptics than to typical neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 844497     DOI: 10.1016/0014-2999(77)90358-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

1.  Effects of chlorimipramine on the synthesis and metabolism of dopamine in the rat striatum.

Authors:  S A Persson
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

2.  Dose-response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies.

Authors:  W H Chang; T Y Chen; H S Wu; W H Hu; E K Yeh
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Evidence for a dopaminergic dominance in the 4,alpha-dimethyl-m-tyramine-induced hypermotility in mice.

Authors:  C Rüdeberg
Journal:  Psychopharmacology (Berl)       Date:  1978-12-08       Impact factor: 4.530

5.  Effect of clomipramine on monoamine metabolites in the cerebrospinal fluid of behaviorally normal dogs.

Authors:  C J Hewson; U A Luescher; J M Parent; R O Ball
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

6.  Effects of carbamazepine and anti-depressant drugs on endogenous catecholamine levels in the cerebroventricular compartment of the rat.

Authors:  S Kowalik; M Levitt; A I Barkai
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Dopamine receptors in canine caudate nucleus.

Authors:  H Maeno
Journal:  Mol Cell Biochem       Date:  1982-03-19       Impact factor: 3.396

8.  Bromperidol, a new butyrophenone neuroleptic: a review.

Authors:  B Dubinsky; J L McGuire; C J Niemegeers; P A Janssen; H S Weintraub; B E McKenzie
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

10.  Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.

Authors:  C Köhler; L Haglund; S O Ogren; T Angeby
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.